!. Abréviations, !. Ssrb, !. Survie, !. Sans!rechute!biochimique, !. Ssrm et al., Sans!Rechute!Métastatique!4!SS7TSA,!Survie!Sans!Traitement!par!Suppression!Androgénique!4!SG,!Survie! Globale!4!SSpM,!Survis!Spécifique!de!la!Maladie!4!M+,!Métastase!4!Ggli,!ganglionnaire!4!RCS,!Radiothérapie!en!Condition!Stéréotaxique!4!TSA,!Traitement!par!Suppression!Androgénique! 4!conco,!concomitant!4!TEP7choline,!Tomographie!par!Émission!de!Positons!couplée!au!scanner!et!marquée!à!la!choline!4!SIB,!Simultaneous

, Survie'Sans'Rechute'Biochimique'(SSRB)'(critère'd'évaluation'principal

!. Ost, !(18)!(seul!essai!prospectif,!62!patients

, Survie'Sans'Rechute'Métastatique'(SSRM

, Temps'de'doublement'du'PSA''(TD>PSA)!

, Métastases'ganglionnaires'exclusives'versus'non'exclusives'

, Temps'de'doublement'du'PSA''(TD>PSA)!

, Bien!que!les!populations!ne!soient!pas!identiques,!les!SG!des!essais!rétrospectifs!publiés

, Délai'diagnostic'initial'-'rechute'oligométastatique

. Survie'spécifique'de'la'maladie,

, ! ! Incidence'de'la'Résistance'à'la'Castration'

, 3%! (n=38)! et! 11,4%! des! cas! (n=13),! respectivement.! Seul! un! cas! (0,9%)! de!

. L'essai!oriole!, )!est!un!essai!de!phase!II,!randomisé,!en!cours!d'inclusion,!qui!étudie!

&. Dans!-le!-bras!-'tsa!-+!-tcm!-par!-rcs',

. Le!rein and !. Le!foie,

. Tumorale!-:!-carcinomes!-mammaire, ! différencié! de! la! thyroïde,!bronchique!non!à!petites!cellules,!glioblastome!et!lymphome!folliculaire.!D'autre! part,! certaines! lésions! bénignes! sont! également! avides! de! PSMA! :! maladie! de! Paget

D. Sur,

H. I. Scher and G. Heller, Clinical states in prostate cancer: toward a dynamic model of disease progression, Urology. 1 mars, vol.55, issue.3, pp.323-330, 2000.

F. H. Schröder, J. Hugosson, M. J. Roobol, T. Tammela, M. Zappa et al., Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, The Lancet. 6 déc, vol.384, issue.9959, pp.2027-2062, 2014.

F. Rozet, C. Hennequin, J. Beauval, P. Beuzeboc, L. Cormier et al.,

, Recommandations françaises du Comité de Cancérologie de l'AFU -Actualisation 2018-2020!: cancer de la prostate, vol.28, 2018.

S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, F. J. Dorey et al., Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy, JAMA. 27 juill, vol.294, issue.4, pp.433-442, 2005.

M. J. Beresford, D. Gillatt, R. J. Benson, and T. Ajithkumar, A Systematic Review of the Role of

P. Cornford, J. Bellmunt, M. Bolla, E. Briers, D. Santis et al., EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and CastrationResistant Prostate Cancer, European Urology. 1 avr, vol.71, issue.4, pp.630-672, 2017.

S. Sridharan, A. Steigler, N. A. Spry, D. Joseph, D. S. Lamb et al.,

S. Hellman and R. R. Weichselbaum, Oligometastases. JCO. 1 janv, vol.13, issue.1, p.10, 1995.

D. K. Reyes and K. J. Pienta, The biology and treatment of oligometastatic cancer, Oncotarget. 13 avr, vol.6, issue.11, pp.8491-524, 2015.

M. H. Umbehr, M. Müntener, T. Hany, T. Sulser, and L. M. Bachmann, The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis, European Urology. 1 juill, vol.64, issue.1, pp.106-123, 2013.

D. Sur,

L. Potters, B. Kavanagh, J. M. Galvin, J. M. Hevezi, N. A. Janjan et al., American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology

, Cancer colorectal métastatique | SNFGE.org -Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive

D. Sur,

R. R. Weichselbaum and S. Hellman, Oligometastases revisited, Nature Reviews Clinical

P. Ost, A. Bossi, K. Decaestecker, D. Meerleer, G. Giannarini et al.,

, Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature, European Urology. 1 mai, vol.67, issue.5, p.63, 2015.

J. Bibault, Rôle de la radiothérapie en conditions stéréotaxiques dans la prise en charge des patients atteints d'un cancer de prostate oligométastatique, Bulletin du Cancer. 1 janv, vol.105, issue.1, p.5, 2018.

P. Ost, D. Reynders, K. Decaestecker, V. Fonteyne, N. Lumen et al., Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial, J Clin Oncol. 10 févr, vol.36, issue.5, pp.446-53, 2018.

N. Radwan, R. Phillips, A. Ross, S. P. Rowe, M. A. Gorin et al., A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, vol.29, p.20, 2017.

/. S1278321817301786/, , 2017.

D. Sur,

J. Cosset, Irradiation hypofractionnée du cancer de prostate!: quelles connaissances radiobiologiques en, 2017.

/. S1278321817301774/, , 2017.

D. Sur,

K. Decaestecker, D. Meerleer, G. Lambert, B. Delrue, L. Fonteyne et al.,

C. A. Jilg, A. Leifert, D. Schnell, S. Kirste, N. Volegova-neher et al., Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer, Radiation Oncology. 12 août, vol.9, p.178, 2014.

P. Berkovic, D. Meerleer, G. Delrue, L. Lambert, B. Fonteyne et al., Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy, Clinical Genitourinary Cancer. 1 mars, vol.11, issue.1, pp.27-32, 2013.

U. Schick, S. Jorcano, P. Nouet, M. Rouzaud, H. Vees et al., Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases, Acta Oncol, vol.52, issue.8, pp.1622-1630, 2013.

N. Suardi, G. Gandaglia, A. Gallina, D. Trapani, E. Scattoni et al., Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years, European Urology. 1 févr, vol.67, issue.2, pp.299-309, 2015.

E. Ponti, G. Ingrosso, A. Carosi, D. Murro, L. Lancia et al., Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience, Clinical Genitourinary Cancer. 1 août, vol.13, issue.4, pp.279-84, 2015.

T. Claeys, C. Van-praet, N. Lumen, P. Ost, V. Fonteyne et al., , vol.85

, Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome

, BioMed Research International, 2015.

P. Disponible-sur-;-ost, B. A. Jereczek-fossa, N. V. As, T. Zilli, A. Muacevic et al., Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis, European Urology. 1 janv, vol.69, issue.1, p.12, 2016.

F. Zattoni, A. Nehra, C. R. Murphy, L. Rangel, L. Mynderse et al., Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy, Eur Urol Focus. déc, vol.2, issue.5, p.31, 2016.

P. Ost, B. A. Jereczek-fossa, N. Van-as, T. Zilli, A. Tree et al., Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences, Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by, vol.28, 2016.

P. Ct, Clinical Genitourinary Cancer, vol.15, issue.5, pp.773-82, 2017.

G. Habl, C. Straube, K. Schiller, M. N. Duma, M. Oechsner et al., Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer. 22 mai, vol.17, p.361, 2017.

G. Ingrosso, F. Trippa, E. Maranzano, A. Carosi, E. Ponti et al., Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience, World J Urol. janv, vol.35, issue.1, pp.45-54, 2017.

M. Cysouw, E. Bouman-wammes, O. Hoekstra, A. Van-den-eertwegh, and P. M. ,

J. Moorselaar, Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics. 1 juin, vol.101, issue.2, p.10, 2018.

S. Tran, S. Jorcano, T. Falco, G. Lamanna, R. Miralbell et al., Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach, American Journal of Clinical Oncology, vol.41, issue.10, pp.960-962, 2018.

C. Franzese, P. A. Zucali, D. Brina, L. , D. Agostino et al.,

F. Würschmidt, C. Petersen, A. Wahl, J. Dahle, and M. Kretschmer,

J. K. Salama, M. D. Hasselle, S. J. Chmura, R. Malik, N. Mehta et al., Stereotactic body radiotherapy for multisite extracranial oligometastases, Cancer, vol.118, issue.11, pp.2962-70, 2012.

A. C. Tree, V. S. Khoo, R. A. Eeles, M. Ahmed, D. P. Dearnaley et al., Stereotactic body radiotherapy for oligometastases, The Lancet Oncology. 1 janv, vol.14, issue.1, pp.28-37, 2013.

T. Inoue, N. Katoh, H. Aoyama, R. Onimaru, H. Taguchi et al., Clinical Outcomes of Stereotactic Brain and/or Body Radiotherapy for Patients with Oligometastatic Lesions, Jpn J Clin Oncol. 1 août, vol.40, issue.8, pp.788-94, 2010.

B. A. Jereczek-fossa, G. Fanetti, C. Fodor, D. Ciardo, L. Santoro et al.,

J. J. Tosoian, M. A. Gorin, A. E. Ross, K. J. Pienta, P. T. Tran et al., Weichselbaum RR. The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment, Nat Rev Urol. janv, vol.14, issue.1, p.50, 2017.

Y. A. Lussier, H. R. Xing, J. K. Salama, N. N. Khodarev, Y. Huang et al., MicroRNA Expression Characterizes Oligometastasis(es). PLoS One, vol.13

A. Uppal, M. K. Ferguson, M. C. Posner, S. Hellman, N. N. Khodarev et al., Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs, Clin Exp Metastasis, vol.31, issue.12, pp.340-52, 2014.

S. Gillessen, G. Attard, T. M. Beer, H. Beltran, A. Bossi et al., Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, vol.73, p.211, 2018.

G. M. Duchesne, H. H. Woo, J. K. Bassett, S. J. Bowe, D. 'este et al., Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA, a randomised, multicentre, non-blinded, vol.17, pp.727-764, 2016.

D. Bari, B. Alongi, F. Lestrade, L. Giammarile, and F. , Choline-PET in prostate cancer management: The point of view of the radiation oncologist, Critical Reviews in Oncology/Hematology. 1 sept, vol.91, issue.3, pp.234-281, 2014.

K. Contractor, A. Challapalli, T. Barwick, M. Winkler, G. Hellawell et al., Use of

, Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression, Clin Cancer Res. 15 déc, vol.17, issue.24, pp.7673-83, 2011.

A. J. Stephenson, P. T. Scardino, M. W. Kattan, T. M. Pisansky, K. M. Slawin et al., Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy, J Clin Oncol. 20 mai, vol.25, issue.15, pp.2035-2076, 2007.

M. Perera, N. Papa, M. Roberts, M. Williams, C. Udovicich et al., , p.68

, Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostatespecific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis, European Urology, vol.14, issue.2019, p.30095

P. De-visschere, C. Standaert, J. J. Fütterer, G. M. Villeirs, V. Panebianco et al., A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer, Eur Urol Oncol. févr, vol.2, issue.1, pp.47-76, 2019.

C. A. Jilg, V. Drendel, H. C. Rischke, T. Beck, K. Reichel et al., Detection Rate ! 87! of 18F-choline-PET/CT and 68Ga-PSMA-HBED-CC-PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes, J Nucl Med. 25 janv, 2019.

H. D. Zacho, J. B. Nielsen, U. Haberkorn, L. Stenholt, and L. J. Petersen, 68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature, Clinical Physiology and Functional Imaging, vol.38, issue.6, pp.911-933, 2018.

Z. Keidar, R. Gill, E. Goshen, O. Israel, T. Davidson et al., 68Ga-PSMA PET/CT in prostate cancer patients -patterns of disease, benign findings and pitfalls. Cancer Imaging, vol.18, 2018.

, AFU!:!Association!Française!d'Urologie!

, ASTRO!:!American'Society'of'Therapeutic'Radialogy'and'Oncology' BED!:!Dose!Biologiquement!Efficace! CaP!:!Cancer!de!la!Prostate! ! EAU!:!European'Association'of'Urology

. Gy, Gray!/!fraction! ! HIFU!:!High>Intensity'Focused'Ultrasound!

!. Irm!:!imagerie!par!résonance and . Magnétique,

, ISUP!:!International'Society'of'Urological'Pathology!

!. Om!:!oligométastatique and . Ps!, !Performans!Status! PSA!:!Prostate'Specific'Antigen! ! PSMA!:!Prostate>Specific'Membrane'Antigen!

!. Rt!:!radiothérapie!-!-rte!:!radiothérapie!externe and . Rcs!, !Radiothérapie!en!Condition!Stéréotaxique! ! SIB!:!Simultaneous'Integrated'Boost!

, SSPL!:!Survie!Sans!Progression!Locale!

. Suv!:!standardized, Uptake'Value!(valeurs!de!fixation!normalisée)!

, TSA!:!Traitement!par!Suppression!Androgénique!! ! VMAT!:!Volumetric'Modulated'Arc'Therapy!